Pharma Stocks To Buy - 2017

: Gained 103% , evolving from a rare-disease specialist into a large-cap biotech giant. Blue-Chip & Dividend Leaders

: Led the industry in R&D spending, focused heavily on its blockbuster immunotherapy Keytruda . pharma stocks to buy 2017

While 2017 was a banner year, several headwinds shaped investment strategies: Pharm Exec's Top 50 Companies 2017 | PharmExec : Gained 103% , evolving from a rare-disease

: Held its position as the world's largest pharma company by market cap ($387B in 2017). ⚠️ Key Trends & Risks : Gained 103%

: Gained over 700% after positive Phase 2 data for its epilepsy treatment, ganaxolone.